) were identified. The botanical medicines or natural products were chosen based on anecdotal clinical usage and preclinical data from the literature. Primary criteria for selecting 1 4 0 compounds for the present study included agents that had shown significant anti-borrelial effects in biofilm effects and ability to cross the blood brain barrier. Botanical medicines were sourced from KW Botanicals (San Anselmo, California) and Heron Botanicals (Kingston, Washington). Botanicals were identified via macroscopic and organoleptic 1 4 7 methods and voucher specimens are on file with the respective production facilities. Most botanical 1 4 8 medicines were provided as alcohol extracts at 30%, 60%, and 90% alcohol, and the alcohol used anti-apoptotic, anti-inflammatory and anti-excitotoxicity (128-131), One of the active constituents seen from the whole plant extract. Despite the case reports of hepatotoxicity, a dose of 1000 4 1 6 mg/kg daily was identified as the no-observed-adverse-effect level (NOAEL) for this 4 1 7 commercial product was given in animal studies for 90 days (150) . Another study demonstrated 4 1 8 no teratogenicity on Scutelaria baicalensis when given to pregnant mice at doses up to 4 1 9 32g/kg/day (151). shown to have neuroprotective effects in preclinical studies (152) (and in preliminary human Uncaria tomentosa has been found to be safe and to have minimal side effects in a variety of animal diarrhea, abdominal pain, and anemia, were reported, it was thought that the group of solid tumor 4 3 6 patients had experienced health issues from disease progression and not necessarily from the Uncaria (153). One case report was made of allergic interstitial nephritis in a patient with SLE 4 3 8 whose kidney function worsened when taking an Uncaria tomentosa product and improved upon creticus has been shown to contain several active constituents (168), including carvacrol (165).
5 8
Given that our lab previously documented carvacrol to have a significant activity against log and Cistus incanus plant extracts have been used for centuries in traditional medicine without reports of 4 6 4 side effects or allergic reactions (169). In a randomised placebo controlled study of 160 patients, 4 6 5 220 mg per day Cistus incanus was well tolerated with less adverse effects than in the placebo 4 6 6 group (163). In a similar study comparing Cistus incanus to green tea, less adverse effects was 4 6 7 again seen in the Cistus incanus group compared to the green tea group (164). While 4 6 8 pharmacokinetic safety data is sparse, a cell culture study showed that Cistus incanus did not cause any adverse changes on cell proliferation, survival, or cellular receptor function (169). Grapefruit seed extract (GSE) was previously reported to have activity against motile and cystic the current study did not demonstrate any meaningful activity against log phase or stationary phase borrelia species used in culture. In the current study we used B. burgdorferi strain b31 whereas the 4 7 9
2007 study cites "B. afzelii ACA-1 "was used. While both studies used Citrosept ™ brand GSE found to have no detectable levels of contaminants and therefore was used as the GSE source in the 4 8 5 current study. In contrast, a second commercially available brand of GSE (Nutribiotic ™ ) did test A 7-day old B. burgdorferi stationary phase culture was treated with the natural product extracts at 1%, 0.5% and 0.2% for 7 days followed by staining with SYBR Green I/PI viability assay and fluorescence microscopy. A 7-day stationary phase B. burgdorferi culture was treated with the indicated natural product extracts for 7 days followed by washing and resuspension in fresh BSK-H medium and subculture for 21 days. The viability of the subculture was examined by SYBR Green I/PI stain and fluorescence microscopy. S  t  a  n  e  k  G  ,  R  e  i  t  e  r  M  .  T  h  e  e  x  p  a  n  d  i  n  g  L  y  m  e  B  o  r  r  e  l  i  a  c  o  m  p  l  e  x  --c  l  i  n  i  c  a  l  s  i  g  n  i  f  i  c  a  n  c  e  o  f  g  e  n  o  m  i  c  s  p  e  c  i  e  s  ?  C  l  i  n  i  c  a  l  m  i  c  r  o  b  i  o  l  o  g  y  a  n  d  i  n  f  e  c  t  i  o  n  :  t  h  e  o  f  f  i  c  i  a  l  p  u  b  l  i  c  a  t  i  o  n  o  f  t  h  e  E  u  r  o  p  e  a  n  S  o  c  i  e  t  y  o  f  C  l  i  n  i  c  a  l  M  i  c  r  o  b  i  o  l  o  g  y  a  n  d  I  n  f  e  c  t  i  o  u  s  D  i  s  e  a  s  e  s  .  2  0  1  1  ;  1  7  (  4  ) : . 
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